Cipla Achieves Highest Ever Revenue in 90th Annual General Meeting; Declares ₹13 Dividend

Cipla Achieves Highest Ever Revenue in 90th Annual General Meeting; Declares ₹13 Dividend​

Cipla Limited celebrated its 90th anniversary and reported robust performance at its 90th Annual General Meeting held on June 25, 2026. The company announced its highest-ever yearly revenue of more than ₹28,000 crores, delivering a 13.8% margin on profit after tax while maintaining strong financial discipline across all key markets.

The meeting featured extensive presentations from the management team, highlighting Cipla’s continued growth trajectory and commitment to making medicine accessible globally. During the session, the company also ratified operational audits, announced product pipeline expansions, and outlined its strategy for reaching a century-old milestone by 2035.

Key Financial Highlights and Market Growth​

Achin Gupta, Managing Director and Global Chief Executive Officer, detailed the strong performance, noting that despite the challenging market, Cipla continued to grow across its prescription, generic, and consumer segments. The company’s India business saw a 9% year-on-year growth and exceeded ₹12,500 crores for the first time.

Geographically, the company demonstrated significant expansion:

• North America: Generated $780 million in revenue.
• One Africa: Achieved $483 million in revenue, reflecting 7% growth, which was 1.4 times the market growth rate.
• Emerging Markets: Exceeded the $400 million mark in revenue.

Cipla now serves patients in approximately 80 different countries.

The company’s financial health remains strong. Despite incurring capital expenditures to expand manufacturing facilities, cash reserves increased from roughly ₹5,000 crores to ₹11,000 crores by FY2026. Cipla maintains a commitment to innovation, dedicating 7% of total revenue toward Research and Development (R&D).

Operational Excellence and Strategic Focus​

In the domestic market, Cipla remains the number one pharmaceutical company in volume terms in India as of MAT March 2026. The company has established leadership across various therapeutic areas including respiratory conditions, diabetes, cardiology, urology, and dermatology. Furthermore, its consumer business stands as the second largest over-the-counter (OTC) enterprise in India.

Cipla is expanding its global footprint through complex product development and strategic partnerships. The company secured approval for a generic Ventolin inhaler at its Fall River facility in the US, illustrating progress in manufacturing complex products outside of India. Cipla also expanded its portfolio by acquiring Inzpera for pediatric treatments and partnered with Eli Lilly on GLP-1 product Yurpeak.

On the international front, Cipla is focused on growth through innovation in markets like North America, where its share of prescription inhalation products has reached nearly 19.6% for Albuterol. The company's strategy involves pursuing differentiated and complex products to ensure both growth and profitability.

Commitment to Sustainability and Social Impact​

Cipla reinforced its commitment to social responsibility (CSR) and environmental stewardship.

• CSR: The Palliative Care Hospital in Pune, which has completed 29 years, continues to expand its influence. Across the country, Cipla’s palliative support system now services over 65,000 patients through 37 partners in 20 states.
• Environmental Impact: The company achieved a 2.6 times water positivity status and is utilizing 84% renewable electricity across its facilities. There was also zero fatality reported in manufacturing operations for the previous year.

Corporate Governance and Resolutions​

The Annual General Meeting covered several critical corporate governance matters:

Investor Outlook and Future Strategy​

Looking ahead, Cipla has outlined a three-pillar strategy aimed at preparing for its centenary in 2035:
1. Leadership in Home Markets: Strengthening market leadership in India across chronic diseases and generics franchise development.
2. Differentiated Products in North America: Focusing on high-quality, lower-cost treatments through complex products.
3. Market Consolidation in Africa and Europe: Strengthening presence and focusing on patient-centric innovation.

During the Q&A session, management addressed questions regarding R&D investment, which was noted as a vital commitment to the future pipeline. The company also provided reassurance regarding quality compliance issues, confirming that the Goa facility had recently cleared an inspection classified as VAI (Voluntary Audit Inspection).

CIPLA Stock Price Movement​

Cipla Limited shares edged higher on Friday, closing the session at ₹1458.2 after gaining ₹1.90 (0.13%) from the previous close. The stock saw significant activity during the day, with 1.26 million shares transacting across the market.